CCS Cell Culture Service Signs Strategic License Agreement with CEVEC Pharmaceuticals
Published: Monday, November 05, 2012 Last Updated: Monday, November 05, 2012
Companies announced today the signing of a strategic license agreement. The license will enable CCS to offer its customers transiently transfected CAP-TTM cells for cell based assay and protein production applications.
Full access to this article is for registered users only. Registration is free-of-charge and allows access to all content on our web communities.
Already registered? Then please log in at the top of the page.